ReviewFrontiers in neuroscience2020
The Pharmacologic Treatment of Stuttering and Its Neuropharmacologic Basis.
Review in Frontiers in neuroscience, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07215884 (Dopamine and Sensorimotor Function in Stuttering), which is not on this map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Dopamine and Sensorimotor Function in Stuttering
Who cites it
25 citing papers in PubMed, 65 citations in OpenAlex.
- Using the DIVA model to better understand speech motor disorders.Clinical linguistics & phonetics · 2026Article
- Exploring Photobiomodulation as a Potential Novel Intervention for Developmental Stuttering: A Review and Hypothesis.Journal of clinical medicine · 2026Review
- Unraveling the mystery of stuttering: clinical and physiological insights into its manifestation.Frontiers in human neuroscience · 2026Article
- A tardive dyskinesia drug target VMAT-2 participates in neuronal process elongation.Scientific reports · 2025Article
- A case of clozapine-induced stuttering in a HIV-positive individual.The South African journal of psychiatry : SAJP : the journal of the Society of Psychiatrists of South Africa · 2025Article
- An active inference account of stuttering behavior.Frontiers in human neuroscience · 2025Article
- Article
- Localization of stuttering based on causal brain lesions.Brain : a journal of neurology · 2024Article
- Psychedelics in developmental stuttering to modulate brain functioning: a new therapeutic perspective?Frontiers in human neuroscience · 2024Article
- Resolution of stuttering during ketamine treatment: a case report.Journal of medical case reports · 2023Article
- Dyslexia and Stuttering: An Overview of Processing Deficits and the Relationship Between Them.Cureus · 2023Review
- Stuttering as a spectrum disorder: A hypothesis.Current research in neurobiology · 2023Review
- Motor constellation theory: A model of infants' phonological development.Frontiers in psychology · 2022Article
- The Relationship Between Auditory-Motor Integration, Interoceptive Awareness, and Self-Reported Stuttering Severity.Frontiers in integrative neuroscience · 2022Article
- Elevated iron concentration in putamen and cortical speech motor network in developmental stuttering.Brain : a journal of neurology · 2021Article
- Dopamine, vocalization, and astrocytes.Brain and language · 2021Article
- Expression of FoxP2 in the basal ganglia regulates vocal motor sequences in the adult songbird.Nature communications · 2021Article
- Investigation of Risperidone Treatment Associated With Enhanced Brain Activity in Patients Who Stutter.Frontiers in neuroscience · 2021Article
- Case Report: Deutetrabenazine as an Adjunctive Treatment for Stuttering.Frontiers in psychiatry · 2021Article
- Speech Fluency Improvement in Developmental Stuttering Using Non-invasive Brain Stimulation: Insights From Available Evidence.Frontiers in human neuroscience · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stuttering is a DSM V psychiatric condition for which there are no FDA-approved medications for treatment. A growing body of evidence suggests that dopamine antagonist medications are effective in reducing the severity of stuttering symptoms. Stuttering shares many similarities to Tourette's Syndrome in that both begin in childhood, follow a similar male to female ratio of 4:1, respond to dopamine antagonists, and symptomatically worsen with dopamine agonists. In recent years, advances in the neurophysiology of stuttering have helped further guide pharmacological treatment. A newer medication with a novel mechanism of action, selective D1 antagonism, is currently being investigated in FDA trials for the treatment of stuttering. D1 antagonists possess different side-effect profiles than D2 antagonist medications and may provide a unique option for those who stutter. In addition, VMAT-2 inhibitors alter dopamine transmission in a unique mechanism of action that offers a promising treatment avenue in stuttering. This review seeks to highlight the different treatment options to help guide the practicing clinician in the treatment of stuttering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.